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total blood products requirement during liver transplantation.
Patients and method: The study includes 30 patients suffering from end-stage liver disease with
MELD (model for end-stage liver disease) classiﬁcation ranging from 15 to 24. The patients were
divided into two equal groups: Group I: The patients were given placebo (100 mL) normal saline
(NS). Group II: The patients were given 2 g Mg in 100 mL NS.
Results: In group II signiﬁcant decrease in CT (clotting time) in EXTEM (which evaluates the
extrinsic pathway after addition of tissue factor), INTEM (which evaluates the intrinsic pathway
after contact activation), APTEM (assess ﬁbrinolytic pathway) and FIBTEM (assess ﬁbrinogen
level after tissue factor activation), decrease in clot formation time (CFT) in EXTEM, increase
a-angel (the angle determined from the reaction time to the inﬂection point of the amplitude of
the forming clot), in INTEM and FIBTEM and increase A10 (clot strength after 10 min) EXTEM,
FIBTEM and APTEM in comparison with group I.a University Hospital, Farid
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Figure 1 The main stream of the b
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assessed by laboratories not clinically. (2) Mg improved coagulation in patients about to undergo
liver transplantation who showed ROTEM evidence of hypocoagulability.
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The signiﬁcance of magnesium and its relationship to the origin
of life has been traced from the composition of the earth’s crust
(rich in iron–magnesium) and the primeval ocean rich in mag-
nesium. The central role of magnesium within the chlorophyll
molecule and as a co-factor for the enzymes in the 12 trans-
phosphorylation reaction in photosynthesis make it probably
the most important inorganic element in the production of food
and fossil fuels [1]. Calcium ions are the essential constituents of
the coagulation cascade. However, participation of Mg ions in
this mechanism has been ignored, recently folding of the native
tertiary structure of factor IX requires not only Ca but also Mg
ions, as factor IX has a speciﬁc binding site(s) for Mg ions
(Fig. 1) that does not interact with Ca ions, and, moreover, that
the binding of Mg ions promotes additional changes in the Ca
bound conformation of the molecule [2]. The Ca-dependent
activation of factor IX by the intrinsic pathway activator factor
XIa was accelerated by Mg ions. Thus, the Mg-induced addi-
tional conformational change appears to enhance the protein’s
ability to function. The activation by factor XIa is, however,
not essential for physiological coagulation. Therefore, the ef-
fect of Mg ions on the function of factor IX in the coagulation
pathway initiated by VIIa {TF} [4].
The liver plays a major role in hemostasis, as most of the
coagulation factors, anticoagulant proteins and components
of the ﬁbrinolytic system are synthesized by hepatic parenchy-
mal cells. Additionally, the reticuloendothelial system of the li-
ver helps to regulate coagulation and ﬁbrinolysis by clearing
these coagulation factors from the circulation [3]. Patients with
end-stage liver disease usually show hypomagnesaemia before
liver transplantation due to decreased intake and gastrointesti-
nal absorption of magnesium, increased excretion of magne-
sium due to laxatives used to prevent hepatic coma and
diuretics used to treat ascites and is accompanied by hypoka-
lemia and hypocalcaemia. Hypomagnesaemia worsens during
liver transplantation, because of massive blood transfusion
since the anticoagulant citrate absorbs magnesium as well as
calcium ions and causes cardiovascular instability such as the
development of perioperative cardiac arrhythmias [5]. The eti-
ology of impaired hemostasis resulting from abnormal liverlood coagulation cascade.function is often multifactorial and may include impaired
coagulation factors synthesis, synthesis of dysfunctional coag-
ulation factors, increased consumption of coagulation factors,
altered clearance of activated coagulation factors and quanti-
tative and qualitative platelet disorders [3].
Point of care (POC) monitoring devices assessing the visco-
elastic properties of whole blood, i.e. thromboelastography
(TEG), rotational thromboelastometry (ROTEM) and Sono-
clot analysis, may overcome several limitations of routine
coagulation tests in the perioperative setting [6].
The term ‘‘TEG’’ was introduced by Hartert in his ﬁrst
publication on thromboelastography in 1948. Surprisingly, in
1993, an American company obtained a trade mark on this
term in the USA, after 45 years of its use as a generic medical
term. In order to achieve a global uniformity of the name, the
manufacturer of the ROTEM system (Pentapharm GmbH,
Munich) has renamed its instrument from ‘‘ROTEG’’ into
‘‘ROTEM’’ and the tests accordingly from ‘‘EXTEG’’ into
‘‘EXTEM’’, ‘‘INTEG’’ into ‘‘INTEM’’ etc. in 2003. ‘‘TEM’’
thereby stands for ‘‘thromboelastometry’’ (analogous to the
term thromboelastography), thus the plotting of the clot ﬁrm-
ness [7].
2. Patients and methods
After approval of local ethical committee and patients in-
formed consent was obtained, the study was done on 26 male
and 4 female patients suffering from end-stage liver disease
with MELD classiﬁcation ranging from 15 to 24.The patients
were randomly allocated by closed envelopes into two equal
groups: group (I) (control group): the patients were given pla-
cebo 100 mL of normal saline (NS) infused (IV) over 5 min
and group II (study group): the patients were given 2 g Mg
in 100 mL NS infused IV over 5 min. Patients scheduled for li-
ver re-transplantation, patients with portal vein thrombosis,
patients with previous major abdominal surgery and patient
with platelet count <50,000 · 103/lL were excluded from the
study. The surgical team and personnel inside the operating
room were blinded to the assigned technique; the same surgical
team operated on all cases.
Rotational thromboelastometry (ROTEG 05) generated
data were obtained from a computer controlled (software ver-
sion linux S/W 1.0.6). ROTEM system (Pentapharm, Munich,
Germany). This ROTEG includes four channel instrument
computer, activators and disposable cups and pins. For quality
assurance the ROTEM system was assessed with ROTROL N
(lyophilized normal plasma) without activator (NATEM) with
partial thromboplastin phosopholipids made from rabbit brain
(INTEM) and with thromboplastin from rabbit brain (EX-
TEM) The ROTEM analyses were performed by electronic
pipette that mixes blood into plastic cup with the speciﬁc re-
agent the reduction in the pin’s movement caused by the clot
was mathematically transformed into ﬁrmness amplitude and
plotted against time, resulting into thromboelastomeric traces.
Table 1 Demographic data of the studied groups.
Group (I) Group (II) P
Age (mean) 48.7 ± 5.5 47.8 ± 5.8 >0.05
Weight (mean) 63.4 ± 5.94 61.7 ± 6.51 >0.05
Table 2 Causes of liver cell failure.
Group I Group II Total
No. No. No.
HCV 8/15 8/15 16/30
HCV and HBV 3/15 4/15 7/30
HCV and BIL 1/15 1/15 2/30
BIL 1/15 1/15 2/30
HCV and HCC 2/15 0/15 2/30
HCC 0/15 1/15 1/30
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studied using ROTEM hemostasis systems. Clot initiation
was denoted by (CT), which the time required to obtain
2 mm amplitude following the initiation of data collection, clot
propagation was designated by the alpha (a) angle, (CFT) is
the time from initiation of clotting until a clot ﬁrmness of
20 mm is detected and clot strength after 10 min was desig-
nated by (A10).We performed the following ROTEM assays,
EXTEM, INTEM, APTEM and FIBTEM and platelet
antagonism.
For every patient and Prior to skin incision, a central ve-
nous catheter introduced through the right internal jugular
vein was used to draw a 4 mL blood sample using the two syr-
inge technique were immediately mixed with 0.5 mL of 3.2%
citrated sodium solution then underwent ROTEM analysis
to obtain a base line assessment. Half the patients in the trial
were infused with 2 g MgSO4 mixed with 100 mL normal sal-
ine over 5 min. The other half were infused with placebo. After
a 10 min interval another blood sample was withdrawn usingTable 3 Hemodynamic data of the patients.
HR SBP
Group (I) Group (II) Group (I) Group (I
Before Mg 81.8 ± 11.4 81.8 ± 11.4 130.0 ± 14.2 130.3 ±
After Mg 80.4 ± 13.1 76 ± 7.1 130.1 ± 12.1 121.4 ±
T 1.19 2.35 0.05 4.15
P >0.05 <0.05* >0.05 <0.001*
Table 4 Laboratory data of the patient.
PT PC
Group (I) Group (II) Group (I) Group (
Before Mg 17.6 ± 2.2 18.5 ± 1.2 48.6 ± 10.6 49.8 ± 7
After Mg 17.86 ± 2.1 17.3 ± 1.3 49.6 ± 13.1 50 ± 7.5
T 1.5 11.61 0.7 0.77
P >0.05 <0.001** >0.05 >0.05the same technique to determine ROTEM changes. No other
drugs were given during the 10 min interval. Other blood sam-
ples withdrawn before and after infusion were sent to the lab-
oratory to measure the serum Mg concentration, PT, PTT,
INR and PC.
3. Statistical analysis
The collected numerical data were presented as mean, standard
deviation. Categorical data were presented as number. Data
were analyzed using Statistical Package of Social Science
(SPSS) version 16. Student t test was used to analyze the data.
Changes between means P values of <0.005 were considered
signiﬁcant.
4. Results
4.1. Demographic features of patients
The demographic data of the patients had no signiﬁcant corre-
lation (Table 1).
4.1.1. Causes of liver cell failure
The patients of group (I) were; 8/15 patients with HCV, 3/15
patients with HCV and HBV, 1/15 patient with HCV and bil-
harizial cirrhosis, 1/15 patient with bilharizial cirrhosis, 2/15
patients with HCV and HCC and 0/15 patient with HCC.
The patients of group (II) were; 8/15 patients with HCV, 4/
15 patients with HCV and HBV, 1/15 patient with HCV and
bilharizial cirrhosis, 1/15 patient with bilharizial cirrhosis, 0/
15 patient with HCV and HCC and 1/15 patient with HCC
(Table 2).
4.1.2. Hemodynamic and laboratory data
In group II, heart rate and systolic blood pressure were signif-
icantly but central venous pressure and diastolic blood pres-
sure showed no signiﬁcant changes (Table 3). PT and PTT
were highly signiﬁcantly decreased but PC and INR were not
signiﬁcantly changed (Table 4).DBP CVP
I) Group (I) Group (II) Group (I) Group (II)
14.1 82.7 ± 12.5 83.5 ± 11.9 12.47 ± 2.5 12.47 ± 2.4
14.2 82.5 ± 11.1 78 ± 11.3 12.9 ± 2.2 12.9 ± 2.3
0.07 1.6 1.29 1.28
* >0.05 >0.05 >0.05 >0.05
INR PTT
II) Group (I) Group (II) Group (I) Group (II)
1.71 ± 0.18 1.6 ± 0.15 39.6 ± .3.6 42.94 ± 3.2
1.72 ± 0.2 1.58 ± 0.16 40.8 ± 4.4 38.48 ± 3.9
0.97 0.01 0.63 4.54
>0.05 >0.05 >0.05 <0.001**
Table 5 Comparison between the two groups as regards blood products requirement.
Group I Group II t P
No. Mean ± SD No. Mean ± SD
Blood 15 10.93 ± 2.865 15 10.93 ± 2.685 0.01 >0.05
Plasma 15 17.47 ± 1.807 15 17.73 ± 2.404 0.3 >0.05
Platelet 15 13.60 ± 8.007 15 13.20 ± 7.243 0.1 >0.05
Cryoprepecitate 15 3.00 ± 0.845 15 3.00 ± 0.926 0.01 >0.05
Table 6 ROTEM data.
Before After T P
No. Mean ± SD No. Mean ± SD
CT in EXTEM 15 85.93 ± 14.429 15 57.60 ± 16.172 6.4 <0.001
CT in INTEM 15 207.87 ± 32.240 15 171.40 ± 35.936 5.8 <0.001
CT in FIBTEM 15 66.73 ± 22.899 15 47.13 ± 12.861 3.7 <0.05
CT in APTEM 15 160.00 ± 313.786 15 65.00 ± 13.638 4.26 <0.001
CFT in EXTEM 15 234.53 ± 68.039 15 193.60 ± 68.517 5.6 <0.001
CFT in INTEM 15 237.87 ± 97.798 14 240.79 ± 94.190 1.1 >0.05
CFT in FIBTEM 12 631.67 ± 405.372 11 741.17 ± 139.943 0.9 >0.05
CFT in APTEM 12 249.67 ± 119.114 14 192.43 ± 85.208 1.9 >0.05
a-angel in EXTEM 15 60.93 ± 10.573 15 66.87 ± 10.426 1.8 >0.05
a-angel in INTEM 15 67.60 ± 13.700 15 71.00 ± 13.099 2.3 <0.05
a-angel in FIBTEM 12 65.33 ± 11.023 10 69.20 ± 10.830 2.3 <0.05
a-angel in APTEM 15 60.07 ± 12.702 15 64.87 ± 15.914 1.2 >0.05
A10 in EXTEM 15 35.40 ± 7.510 15 38.00 ± 5.237 2.6 <0.05
A10 in INTEM 15 37.40 ± 11.274 15 38.13 ± 11.319 0.6 >0.05
A10 FIBTEM 13 7.38 ± 3.280 12 10.00 ± 2.594 4.2 <0.01
A10 APTEM 13 39.54 ± 14.931 14 44.14 ± 12.322 3.2 <0.05
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Comparison between two groups with and without Mg in
blood, plasma, platelet and cryoprepcitate requirement showed
non signiﬁcant differences (Table 5).
4.1.4. ROTEM data
There were highly signiﬁcant decreases in CT in EXTEM, IN-
TEM, APTEM and signiﬁcant decrease CT in FIBTEM.
There were also highly signiﬁcant decreases in CFT in EX-
TEM and signiﬁcant increases in a-angel in INTEM, FIBTEM
ﬁnally highly signiﬁcant increase in A10 in FIBTEM and sig-
niﬁcant increase EXTEM and APTEM (Table 6).
5. Discussion
In accordance with our hypothesis and based on previous data,
we found that magnesium therapy improved coagulation in
patients about to undergo liver transplantation who showed
ROTEM evidence of hypocoagulability. The fact that end-
stage liver disease patients show ROTEM ﬁndings of general
hypocoagulability had already been reported [6,8].
Our ﬁndings as decreases in CT in EXTEM, INTEM, AP-
TEM and FIBTEM after Mg infusion were considered as
means to decrease the time of beginning of clot formation,
to help in activation extrinsic and intrinsic pathways, to help
to increase ﬁbrin formation and to improve speed of cross
linking. Increased a-angel in INTEM and FIBTEM after Mg
infusion was considered the result of increased propagationof the clot. Increased A10 in EXTEM, FIBTEM and APTEM
after Mg infusion was considered the result of increased
strength of the clot.
Most commonly, routine laboratory-based coagulation
tests (e.g., PT, INR, APTT, and ﬁbrinogen) and platelet count
are being used to assess the patient’s current coagulation sta-
tus. However, the value of these tests has been questioned in
the acute perioperative setting because there are delays from
blood sampling to obtaining results (45–60 min), coagulation
tests are determined in plasma rather than whole blood, no
information is available on platelet function (PF) and the as-
says are performed at a standard temperature of 37 C rather
than the patient’s temperature [9].
TEG/ROTEM both measure and graphically display the
changes in viscoelasticity at all stages of the developing and resolv-
ing clot, i.e., the time until initial ﬁbrin formation (TEG reaction
time; ROTEM clotting time [CT]), the kinetics of ﬁbrin formation
and clot development (TEGkinetics, a angle;ROTEMclot forma-
tion time, a angle, the ultimate strength and stability of the ﬁbrin
clot (TEG maximum amplitude [MA]; ROTEM maximum clot
ﬁrmness [MCF]), and clot lyses (ﬁbrinolysis) [10].
Jong et al. denoted decreased potassium (K) and coagula-
tion time (r+ k) after magnesium therapy as the result of in-
creased early ﬁbrin formation and improved speed of cross
linking. Increased maximum amplitude (MA) was thought to
be a result of improved clot strength secondary to improved
function of platelets. The increased TEG index suggests an
overall improvement in coagulation [5].
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coagulation following the administration of therapeutic
doses of Mg. The only signiﬁcant change was in a-angel
which actually suggested an increase in coagulant activity
[11]. No signiﬁcant change was seen on the TEG when
healthy volunteers were treated with magnesium. The claim
that the effect of magnesium on the coagulation system is
insigniﬁcant is based on an in vitro study [12]. Briel et al.
also investigated the effect of magnesium on thromboelas-
tography and demonstrated inhibitory inﬂuences on all mea-
sured parameters. These studies were, however, in vitro and
although both showed signiﬁcant changes in thromboelasto-
graphic parameters, neither claimed clinical signiﬁcance [13].
Wall et al., compared normal women in labor with women
in premature labor receiving magnesium, again using throm-
boelastography, and concluded no differences [14]. Fuentes
et al. demonstrated, in vivo, that magnesium appears to pro-
long the bleeding time in pregnancy [15].
Jong et al., recommended that a study is needed to investi-
gate the effect of magnesium therapy and the improvement of
TEG variables on blood product requirements during liver
transplantation to conﬁrm the ﬁndings when using ROTEM
[5].
5.1. Our results must be interpreted with caution
First, the number of patients were 30 because of limited donors
and the high cost. Second, the device gives multiple Code error,
according to the representative of the manufacturer (Pentap-
harm Gmbh) in Egypt, 4033 Firmness cannot be determined
due to mechanical failure, 3023 Cuvette or pin not correctly
placed, 5043 Axis heavily disturbed during placing of pin
OR Damaged Ball Bearing on axis, 10003 and 6033 Running
measurement inﬂuenced by drying of sample. Errors 4033,
3023, 6033 and 10003 are Operation/User Errors; that can be
overcome by correct operation. If error 5043 appears only
once or twice, can be a random error; but; if appeared fre-
quently then instrument needs some maintenance service.
Third, the cause of human error and drying sample may be
due to use of multiple reagents and seven steps of the pipetting.
The number of all results from ROTEM with and without Mg,
before and after Mg infusion were 960 and the number of error
of sample 58 which represented 6.04% was excluded from the
results.
6. Conclusion
1. The ROTEM analysis shows the effect of Mg ions
in coagulation that can be assessed laboratories not
clinically.2. Mg improves coagulation in patients about to undergo liver
transplantation who showed ROTEM evidence of
hypocoagulability.7. Recommendations
First, to increase the number of patients. Second, to use single
shot reagents. Third, to decrease the number of steps and de-
crease reagents waste decreasing the cost.
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